Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial

Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity. This phase IV trial aims to evaluate the lot-to-lot consistency, immunogenicity, and safety on a commercial scale in healthy adults, which could...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Dandan, Hu, Yuansheng, Jiang, Zhiwei, Yang, Tuantuan, Chu, Kai, Zhang, Hengming, Hu, Jialei, Meng, Xing, Tan, Zhijun, Wu, Jingliang, Lian, Xiaojuan, Li, Changgui, Pan, Hongxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronavirus – Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746504/
https://www.ncbi.nlm.nih.gov/pubmed/36441137
http://dx.doi.org/10.1080/21645515.2022.2135929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746504/
https://www.ncbi.nlm.nih.gov/pubmed/36441137
http://dx.doi.org/10.1080/21645515.2022.2135929

Ejemplares similares